Purpose: To assess the postoperative objective, subjective, and functional outcomes as well as complication rates in osteochondral defect patients treated with bone marrow aspirate concentrate (BMAC) and cartilage-derived matrix (CDM) during knee arthroscopy. Methods: A retrospective chart review was performed for patients treated arthroscopically with BMAC and CDM between August 2015 and August 2018 and had more than 1-year follow-up. Demographic factors such as age, sex, body mass index, and comorbidities were collected for all patients. Size and location of the osteochondral lesions also were documented. Results: A total of 14 patients were identified with a mean follow-up of 19 months. On average, patients were 34 years of age (range 16-58 years) and 43% were female. Postoperatively, knee flexion increased by 8° from 124° to 132° (P = .002). All patients regained full extension; however, 1 patient later acquired a 2° extension contracture after a traumatic event. The average hamstring strength significantly increased from 4.1 to 4.6 postoperatively (P = .33). The average quadriceps strength significantly increased from 4.0 to 4.5 postoperatively (P = .007). Mean visual analog scale scores significantly decreased postoperatively (4.5 vs 1.4; P = .001). There was a significant increase in Knee Outcome Survey Activities of Daily Living scores (53.8 vs 92.9; P = .007). Mean Knee Outcome Survey-Sports scores also increased, although this was nonsignificant (28.2 vs 79.5; P = .560). No significant differences were noted in pain and functional outcomes when stratified by the osteochondral defect size and location. Complications included a stitch abscess, Baker’s cyst, and residual pain treated with hyaluronic acid injection. Conclusions: This study demonstrated arthroscopic BMAC and CDM implantation appears to be safe and has the potential to improve patient outcomes in the short-term postoperative period. Level of Evidence: IV, therapeutic case series.

Osteochondral defects of the knee are identified during more than 60% of arthroscopic procedures.1-3 Due to their limited healing capacity, these lesions remain a challenge to definitively treat.4-6 Given their heterogeneity, several procedures have been formulated to treat symptomatic patients with osteochondral defects based on factors such as defect size, lesion depth, patient age, and concomitant intra-articular pathology.7,8 These procedures include microfracture (MF), juvenile articular cartilage implantation, osteochondral autograft, or allograft, transfer system (OATs), autologous chondrocyte
implantation (ACI), and matrix-induced ACI and are generally indicated based on lesion type. Despite these numerous options, long-term outcomes have shown varied results and the optimal treatment for these defects remains unclear. Thus, newer therapies including biologic and scaffold-based treatments have emerged with efforts to improve postoperative outcomes in patients with focal osteochondral lesions.

Among the biologic therapies, cell-based injections including bone marrow aspirate concentrate (BMAC) have been proposed and applied in clinical practice. Bone marrow-derived mesenchymal stem cells (MSCs) have a theoretical advantage over MSCs from other origins in that they have a greater differentiation capacity and thus are believed to aid in tissue regeneration. Following treatment with BMACs, preclinical studies have demonstrated an increased fill of cartilage defects and well-integrated repair tissue with greater type-II collagen content. Scaffold-based cartilage treatments are another method used in osteochondral defect treatment that also have reached clinical practice. These scaffolds are available as synthetic matrices or as natural materials, including collagen derivates and hyaluronic acid (HA). While cell-based constructs are more commonly studied and yield promising outcomes, cell-free scaffolds also have demonstrated favorable outcomes in the short-term.

Nonetheless, cartilage-derived matrix (CDM) scaffolds have recently gained traction because, in contrast to marrow-stimulating procedures such as MF, the repair tissue has been shown to have better long-term viability. Current osteochondral defect treatments are associated with several drawbacks. MF has questionable durability with poor outcomes beyond the short term and is correlated with low rates of return to play in high level athletes. The OATs procedure is associated with donor-site morbidity, ACI is costly as it requires multiple operations, and with the exception of MF, these procedures cannot be performed through a minimally invasive approach. Hence, BMAC and CDM scaffolds may offer a promising alternative.

In recent years, several new developments have emerged to address osteochondral lesions. Thus, it is important to evaluate the postoperative outcomes among patients who undergo newer biologic and scaffold-based treatments. Therefore, the purpose of this study was to assess the postoperative objective, subjective, and functional outcomes as well as complication rates in osteochondral defect patients treated with BMAC and CDM during knee arthroscopy. Specifically, we assessed the postoperative objective, subjective, and functional outcomes as well as complication rates in patients treated with BMAC and CDM during knee arthroscopy. We hypothesized that osteochondral defect patients treated arthroscopically with BMAC and CDM would have improved postoperative outcomes and no associated adverse events.

Methods

Patient Selection

Following institutional review board approval, we performed a retrospective analysis on patients diagnosed with osteochondral defects of the knee. Patients were included if they were arthroscopically treated with BMAC and CDM implantation by a single, sports-medicine fellowship-trained orthopaedic surgeon at a single, academic institution between August 2015 and August 2018 and had more than 1-year follow-up. Patients with a diagnosis of knee osteoarthritis, based on radiographic analysis (less than 2 mm of joint space on weight-bearing radiographs), or inflammatory arthropathy, who received other forms of treatment, or lacked 1 year of follow-up were excluded. Demographic factors such as age, sex, body mass index, and comorbidities were collected for all patients. Although subchondral one depth was not recorded, other characteristics of the osteochondral lesion obtained during chart review such as size and location also were documented for all patients.

Surgical Indications and Treatment

Patients who presented with knee pain, swelling, mechanical symptoms, limited motion, and functional capabilities were diagnosed with an osteochondral defect lesion and those who did not respond to conservative measures including physical therapy, nonsteroidal inflammatory drug use, and intra-articular injections were indicated for and underwent arthroscopic treatment with BMAC and CDM.

Surgery consisted of bone marrow aspiration and centrifugation (Magellan ISTO Biologics, Hopkinton, MA), defect preparation, BMAC and CDM (Bio-Cartilage; Arthrex, Naples, FL) implantation, and a final intra-articular BMAC injection. A total of 60 mL of bone marrow were aspirated using a Jamshidi needle 3 cm posterior to the anterior superior iliac spine. During aspiration, the syringe was rotated every 5 mL until the total amount was obtained. In sterile fashion, the suspension was concentrated to 7 mL via centrifugation. The amount of MSCs was not evaluated for each patient. One milliliter of BMAC was combined with the cartilage-derived scaffold while the remaining 6 mL were set aside for the intra-articular injection. Before the matrix implantation, diagnostic arthroscopy was performed to identify the presence of and address concomitant pathology. Examples of concomitant procedures included loose body removal, revision anterior cruciate ligament reconstruction, distal femoral osteotomy, revision medial patellofemoral ligament...
reconstruction, lateral release, and partial meniscectomy (Table 1). When present, pathologic patellofemoral or tibiofemoral malalignment was addressed with an osteotomy. Other concomitant procedures were performed when indicated, including the associated presence of preoperative subchondral insufficiency fracture adjacent to the lesion with percutaneous skeletal fixation with calcium phosphate cement (Zimmer subchondroplasty). The osteochondral defect was then identified and debrided to healthy bleeding subchondral bone and a contained rim. The fluid was removed and the lesion was thoroughly dried and grafted with the mixture of 1 mL of BMAC and CDM and covered with fibrin glue. Lastly, the remaining 6 mL of BMAC was injected intra-articularly once the fibrin glue solidified. A full description of the technique has been previously defined.25 Standard perioperative care included 1 preoperative dose of intravenous antibiotics and postoperative thromboembolic prophylaxis with 325 mg of aspirin twice a day. Postoperatively, patients with tibiofemoral lesions were 50% partial weight-bearing for 4 to 6 weeks without a brace while patients with patellofemoral lesions were allowed weight-bearing as tolerated with a hinged knee brace locked in extension for 4 to 6 weeks while weight-bearing. All patients were allowed passive range of motion (ROM) as tolerated with isometric strengthening for 6 weeks followed by a progressive strengthening program. If patients continued with symptoms at 5 months, a series of intra-articular HA injections were offered postoperatively. Postoperative magnetic resonance imaging was not performed on a routine basis.

### Table 1. Demographics for Osteochondral Defect Patients Treated With BMAC and CDM

| Variables                        | n (%) |
|----------------------------------|-------|
| Demographics of the Patients, N  | 14    |
| Sex                              |       |
| Female                           | 6 (42.9) |
| Male                             | 8 (57.1) |
| Age, y                           | 34 (16-58) |
| Number of comorbidities          |       |
| 0                                | 7 (50) |
| 1                                | 3 (21.4) |
| 2                                | 4 (28.6) |
| BMI                              | 27.7 (21.8-37.2) |
| Size of lesion, cm²              | 1.8 (7 - 3.0) |
| Location of lesion               |       |
| Patella                          | 5 (35.7) |
| Lateral femoral condyle          | 5 (35.7) |
| Medial femoral condyle           | 4 (28.6) |
| Trochlea                         | 2 (14.2) |
| Concomitant procedures           |       |
| Loose body removal               | 5 (35.7) |
| Revision ACL reconstruction       | 2 (14.2) |
| Distal femoral osteotomy         | 1 (7.1) |
| Revision MPFL reconstruction     | 1 (7.1) |
| Lateral release                  | 3 (21.9) |
| Partial meniscectomy             | 4 (28.6) |
| Plica excision                   | 2 (14.2) |
| Tibial tubercle osteotomy        | 1 (7.1) |
| Chondroplasty                    | 2 (14.2) |
| Subchondroplasty                 | 3 (21.9) |
| Follow-up, mo                    | 19 (12-31) |

NOTE. Values are given as the mean and range in parentheses.

ACL, anterior cruciate ligament; BMAC, bone marrow aspirate concentrate; BMI, body mass index; CDM, cartilage-derived matrix; LFC, lateral femoral condyle; MPFL, medial patellofemoral ligament; PROM, patient-reported outcome measures.

### Variables

Physical examination findings included ROM (i.e., flexion and extension) and hamstring and quadriceps strength. Passive knee flexion and extension were assessed with the patient in the supine position while manual muscle strength testing, also performed in the supine position, was based on a standard grading scale of 0 to 5. Pain intensity was measured by using visual analog scale (VAS) scores. Functional outcomes were assessed with the University of California Los Angeles Activity Score (UCLA), Knee Outcome Survey Activities of Daily Living (KOS-ADL), and KOS-Sports Scores. Pain and functional outcomes were further stratified based on osteochondral defect size (<2 cm² vs >2 cm²) and location (patella and trochlea vs medial and lateral femoral condyles).8 All objective, subjective, and functional outcomes were assessed at final follow-up. Complications were documented and were defined as wound complications, implant or hardware-related problems, and subsequent surgeries.

### Data Analysis

Descriptive analyses were performed to assess patient demographics and physical examination findings, which were both reported as frequencies. Paired samples t tests and Student t tests were used to compare ROM, muscle strength, pain, and functional outcome scores. Effect size was calculated for ROM, muscle strength, VAS, UCLA, KOS-ADL, and KOS-Sports scores. Effect sizes were considered small, medium, and large if they measured 0.2, 0.5, and 0.8, respectively. χ² tests were performed to compare hamstring and quadriceps strength between patients when stratified by osteochondral defect size and location. A P value of .05 was set as the threshold for statistical significance. All statistical analysis was performed using SPSS, version 22 (IBM Corp, Armonk, NY).

### Results

#### Patients Included in Final Analysis

A total of 75 knee osteochondral defect patients were identified. Of these, 21 patients did not receive CDM implantation and 4 patients did not receive BMAC. Twenty-three patients received other modes of treatment and were thus excluded. Of the remaining patients, 13 had follow-up of less than 1 year. Therefore,
14 patients fit the inclusion criteria and were included for analysis. On average, patients had 19 months of follow-up (range 12-31 months), were 34 years of age (range 16-58 years), and 43% were female (Table 1). The mean body mass index was 27.7 (range 21.8-37.2). The number of comorbidities among the patients ranged from 0 to 2. All patients had an International Cartilage Repair Society (ICRS) grade of IV.26 The average size of the osteochondral defect lesion was 1.8 cm² (range 0.7-3 cm²). The patella and lateral femoral condyle represented the most common locations for the osteochondral defects, followed by the medial femoral condyle and the trochlea. Twelve patients had one osteochondral lesion, whereas 2 patients were found to have 2 lesions; 1 patient had lesions in the patella and trochlea and the other patient had lesions in the lateral and medial femoral condyles. While all patients had at least 1 concomitant procedure, loose body removal (35.7%) and partial meniscectomy (28.6%) were the most commonly performed concomitant procedures. Finally, patient-reported outcome measures were completed by 13 (93%) patients.

**Physical Examination Findings**

Postoperatively, knee flexion increased by 8° from 124° to 132° (P = .002) (Table 2). All patients regained full extension; however, 1 patient later acquired a 2° extension contracture after a traumatic event which affected his operated extremity. Preoperative hamstring strength ranged from 4— to 5 whereas the postoperative strength ranged from 4 to 5. The average hamstring strength significantly increased from 4.1 to 4.6 postoperatively (P = .33). Similarly, preoperative quadriceps strength ranged from 3+ to 5 whereas postoperative strength increased to a range of 4 to 5. The average quadriceps strength significantly increased from 4.0 to 4.5 postoperatively (P = .007). The effect sizes were large (>0.80) in regards to hamstring strength (0.94) and quadriceps strength (0.96).

**Pain and Functional Outcomes**

Mean preoperative VAS scores significantly decreased postoperatively (4.5 vs 1.4; P = .001). There was a slight increase in mean UCLA scores, although this was nonsignificant (5.7 vs 6.6; P = .455). There was a significant increase in postoperative KOS-ADL scores (53.8 vs 92.9; P = .007). Mean KOS-Sports scores also increased, though this was nonsignificant (28.2 vs 79.5; P = .560). No significant differences were noted in pain and functional outcomes when stratified by osteochondral defect size (Table 3). Similarly, there were no differences in pain and functional outcomes when stratified by osteochondral defect location, with the exception of postoperative UCLA scores (Table 4). Patients with patella and trochlea lesions had lower postoperative UCLA scores than patients with femoral condyle lesions (5.5 vs 8.4; P = .04). The effect sizes were large (>0.80) in regards to knee flexion (1.06), VAS (1.32), KOS-ADL (6.76), and the KOS-Sports (1.51). The effect size for the UCLA score was small (0.23).

**Complications**

There was a 29% complication rate, as 4 postoperative complications were documented (Table 5). One patient had a stitch abscess, which resolved with

| Table 2. Clinical and Functional Outcomes of Osteochondral Defect Patients Treated With BMAC and CDM |
| Demographics of the Patients, N = 14 | N (%) | P Value |
| Physical examination findings | | | |
| Preoperative flexion,* | 123.9 (3.6) | .002 |
| Postoperative flexion,* | 131.5 (6.3) |
| Effect size | 1.06 |
| Hamstring* | | | |
| Preoperative strength | | | |
| 4— | 3 (33.3) |
| 4 | 5 (33.6) |
| 5 | 1 (11.1) |
| Postoperative strength | | | |
| 4 | 5 (45.5) |
| 5 | 6 (54.5) |
| Preoperative strength | 4.1 (0.35) |
| Postoperative strength | 4.6 (0.52) | .33 |
| Effect size | 0.94 |
| Quadriceps* | | | |
| Preoperative strength | | | |
| 3+ | 2 (15.4) |
| 4— | 5 (38.5) |
| 4 | 5 (38.5) |
| 5 | 1 (7.7) |
| Postoperative strength | | | |
| 4 | 7 (53.8) |
| 5 | 6 (46.2) |
| Preoperative strength | 4.0 (0.45) |
| Postoperative strength | 4.5 (0.52) | .007 |
| Effect size | 0.96 |
| Pain scores | | | |
| Preoperative VAS | 4.5 (2.4) |
| Postoperative VAS | 1.4 (1.6) | .001 |
| Effect size | 1.32 |
| Functional outcomes | | | |
| Preoperative UCLA | 5.7 (2.4) |
| Postoperative UCLA | 6.6 (2.5) | .455 |
| Effect size | 0.23 |
| Preoperative KOS-ADL | 53.8 (14.3) |
| Postoperative KOS-ADL | 92.9 (12.4) | .007 |
| Effect size | 6.76 |
| Preoperative KOS-Sports | 28.2 (15.7) |
| Postoperative KOS-Sports | 79.5 (20.3) | .560 |
| Effect size | 1.51 |

NOTE. Values are given as the mean and standard deviation in parentheses. ADL, activities of daily living; BMAC, bone marrow aspirate concentrate; CDM, cartilage-derived matrix; KOS, Knee Outcome Survey; UCLA: University of California, Los Angeles Activity Score; VAS, visual analog scale.

*Strength is based on a grading scale of 0-5.
Table 3. Clinical and Functional Outcomes Stratified by Osteochondral Size

|                           | <2 cm² | >2 cm² | P Value |
|---------------------------|--------|--------|---------|
| **Physical examination findings** |        |        |         |
| Preoperative flexion, ° | 126.0 (4.2) | 122 (2.7) | .11     |
| Postoperative flexion, ° | 130.8 (7.4) | 132.0 (4.5) | .77     |
| Hamstring                 |        |        |         |
| Preoperative strength    |        |        |         |
| 4+                       | 0 (0.0) | 3 (60.0) |         |
| 4                        | 4 (66.7) | 0 (0.0) | .03     |
| Postoperative strength   |        |        |         |
| 4                        | 2 (33.3) | 1 (20.0) |         |
| 5                        | 2 (33.3) | 3 (60.0) | .68     |
| Quadriceps               |        |        |         |
| Preoperative strength    |        |        |         |
| 3+                       | 0 (0.0) | 1 (20.0) |         |
| 4                        | 1 (16.7) | 4 (80.0) |         |
| 4                        | 4 (66.7) | 0 (0.0) | .05     |
| Postoperative strength   |        |        |         |
| 4                        | 4 (66.7) | 1 (20.0) |         |
| 5                        | 2 (33.3) | 3 (60.0) | .23     |
| Pain scores              |        |        |         |
| Preoperative VAS         | 4.1 (3.1) | 5.2 (2.6) | .56     |
| Postoperative VAS        | 1.6 (1.5) | 1.2 (2.2) | .74     |
| Functional Outcomes      |        |        |         |
| Preoperative UCLA        | 5.6 (2.9) | 5.0 (3.2) | .78     |
| Postoperative UCLA       | 8.6 (1.1) | 6.0 (3.4) | .17     |
| Preoperative KOS-ADL     | 38.6    | 55.7   |         |
| Postoperative KOS-ADL    | 88.9 (13.0) | 77.1 (27.9) | .43 |
| Preoperative KOS-Sports  | 32.7 (20.5) | 34.5 | .95     |
| Postoperative KOS-Sports | 80.7 (17.9) | 74.2 (21.7) | .62    |

**NOTE.** Values are given as the mean and standard deviation in parentheses.

ADL, activities of daily living; BMAC, bone marrow aspirate concentrate; KOS, Knee Outcome Survey; UCLA, University of California, Los Angeles Activity Score; VAS, visual analog scale.

Discussion

We found that physical examination findings, VAS scores, and KOS-ADL scores significantly improved following BMAC and CDM implantation, with approximately one-third of patients having minor complications and no severe complications. Arthroscopic BMAC and CDM implantation has become one of many treatment options available for osteochondral defects of the knee. Cell-based injections such as BMAC and scaffold-based treatments have demonstrated improvements in cartilage defects in preclinical studies and have now reached clinical practice. Thus, it is important to assess the postoperative outcomes among patients who undergo newer biologic and scaffold-based treatments. Therefore, we aimed to assess postoperative outcomes in patients with osteochondral defects of the knee treated with BMAC and CDM and found favorable results.

The findings of this study include diminished pain and favorable functional outcomes following arthroscopic BMAC and CDM implantation in osteochondral defect patients. It is important to note that the improvement in VAS scores, UCLA, KOS-ADL, and KOS-Sports observed in this study are based on statistical significance. However, several studies have reported the minimally clinical important difference (MCID) or substantial clinical benefit (SCB) for various patient-reported outcome measures to quantify the clinical significance of these values. According to previous studies assessing patients with cartilage defects, the MCID for VAS scores has been reported to be 2.7, the MCID for KOS-ADL was 10 (with a standard deviation (SD) of 3.7), and the SCB for KOS-ADL was 17 (SD of 3.9). Six patients in our study (43%) demonstrated improvements in VAS scores that exceeded the MCID whereas 13 patients (93%) demonstrated improvements KOS-ADL scores that exceeded both the MCID and the SCB. Thus, arthroscopic treatment with BMAC and CDM implantation also may have clinical significance. Although the studies that report these MCIDs are based on patients with cartilage defects, the treatments in these studies varied and included MF, mosaicplasty, OATs, and ACI/MACI. Given the novelty of interventions with biologic and scaffold-based therapies, we believe MCIDs derived from these specific treatments will emerge and better reflect their clinical implications. Despite this, correlating our results with established MCIDs provides valuable insight as to how this intervention may be affecting patients.

Given the advent of newer biologic therapies, several studies, similar to ours, have evaluated clinical outcomes in patients receiving BMAC. In their prospective cohort study, Gobbi et al. evaluated postoperative outcomes in patients with grade IV cartilage defects of the knee, as classified by the ICRS. The authors compared 50 patients treated with MF with 27 patients treated with HA-based scaffold and BMAC and found greater Tegner, International Knee Documentation Committee, and Knee Injury and Osteoarthritis Outcomes Score (KOOS) scores in the HA-BMAC group at 5 years. Another nonrandomized prospective trial performed by Gobbi et al. evaluated outcomes among patients with patellofemoral chondral lesions treated with the same HA-derived scaffold. The authors found that patients treated with BMAC (n = 18) had greater...
International Knee Documentation Committee subjective scores than patients treated with matrix-induced autologous chondrocyte implantation (n = 19) at a minimum of 3-year follow up. Similar to our study, these studies assessed patients with grade IV ICRS defects. In contrast, however, these studies performed miniarthrotomies as the approach for implantation. Although the authors concluded that BMAC is a viable option for the treatment of osteochondral defect of the knee, our study demonstrates similar advantages of BMAC use with an arthroscopic approach albeit in the short term.

Although we describe favorable clinical outcomes, few studies report on clinical outcomes in regards to CDM treatment. Carter et al.32 published a 6-patient case series based on treatment of chondral defects of the knee with MF and BioCartilage. The authors found that KOOS scores ranged from 24 to 93 between 6 and 24 months postoperatively. Despite the variability in scores, the authors found specific findings on magnetic resonance imaging correlate with greater KOOS scores. These include the preservation of greater than 50% thickness compared with surrounding native cartilage, mild irregularity of subchondral plate, vertical low signal intensity lines, and mild or no bone marrow edema. The BioCartilage scaffold consists of extracellular matrix that contains type II collagen, proteoglycans, and growth factors.32 In contrast to MF, which primarily produces fibrocartilage with type-1 collagen, the BioCartilage construct is, in theory, intended to promote regeneration of hyaline-like

| Table 4. Clinical and Functional Outcomes Stratified by Osteochondral Location |
|---------------------------------------------------------------|
| **N (%)** | Patella and Trochlea | Femoral Condyles | **P Value** |
|---------------------------------------------------------------|
| **Physical examination findings** | | | | |
| Preoperative flexion,° | 123.3 (2.6) | 124.3 (4.5) | .66 |
| Postoperative flexion,° | 130.8 (5.8) | 132.5 (6.5) | .63 |
| **Hamstring** | | | | |
| Preoperative strength | | | | |
| 4— | 1 (16.7) | 2 (25.0) | | |
| 4 | 2 (33.3) | 3 (37.5) | | |
| 5 | 0 (0.0) | 1 (12.5) | | |
| Postoperative strength | | | | |
| 4— | 4 (66.7) | 1 (12.5) | | |
| 4 | 2 (33.3) | 4 (50.0) | .07 |
| **Quadriceps** | | | | |
| Preoperative strength | | | | |
| 3+ | 1 (16.7) | 1 (12.5) | | |
| 4— | 3 (50.0) | 2 (25.0) | | |
| 4 | 2 (33.3) | 3 (37.5) | | |
| 5 | 0 (0.0) | 1 (12.5) | | |
| Postoperative strength | | | | |
| 4— | 4 (66.7) | 3 (37.5) | | |
| 4 | 2 (33.3) | 4 (50.0) | .46 |
| **Pain scores** | | | | |
| Preoperative VAS | 5.3 (2.3) | 3.4 (2.5) | .17 |
| Postoperative VAS | 1.7 (2.0) | 1.0 (1.2) | .46 |
| **Functional outcomes** | | | | |
| Preoperative UCLA | 6.5 (2.8) | 4.5 (1.6) | .16 |
| Postoperative UCLA | 5.5 (2.7) | 8.4 (1.8) | .04 |
| Preoperative KOS-ADL | 82.9 (22.7) | 89.6 (18.0) | .56 |
| Postoperative KOS-ADL | 47.2 | 21.8 (11.3) | .19 |
| Preoperative KOS-Sports | 75.7 (20.4) | 85.4 (16.1) | .36 |
| Postoperative KOS-Sports | | | | |

**NOTE.** Values are given as the mean and standard deviation in parentheses.

ADL, activities of daily living; BMAC, bone marrow aspirate concentrate; KOS, Knee Outcome Survey; UCLA: University of California, Los Angeles Activity Score; VAS, visual analog scale.

| Table 5. Complications for Patients With Osteochondral Defect Treated With BMAC and CDM |
|---------------------------------------------------------------|
| **Postoperative complications** | **n (%)** | | |
| Stitch abscess | 1 (7.1) | | |
| Baker’s cyst | 1 (7.1) | | |
| Painful hardware | 1 (7.1) | | |
| HA injection | 1 (7.1) | | |
| Subsequent surgeries | | | | |
| Open cyst excision | 1 (7.1) | | |
| Removal of hardware (two 4.5-mm tibial tubercle screws) | 1 (7.1) | | |
| Mean time to subsequent surgeries, mo | 10.5 (2.9-17.4) | | |

BMAC, bone marrow aspirate concentrate; CDM, cartilage-derived matrix; HA, hyaluronic acid.
cartilage. Given that BMAC and CDM implantation do not lead to donor-site morbidity, require one stage, are less costly, and can be performed through minimally invasive techniques, we believe this may serve as an alternative to conventional treatment (i.e., MF, OATs, ACI, and matrix-induced autologous chondrocyte implantation).

Limitations
This study has several limitations. Due to the retrospective design, it is difficult to establish cause and effect between the intervention and treatment success. The sample size was small, which increased the possibility of a type II error. In addition, this study lacks a control group and longer follow-up, which further limits the scope of our results. One patient received a series of HA injections postoperatively and interventions such as these can influence the results. In addition, the composition of the BMAC preparation was not assessed. BMAC preparation is not standardized in the literature, and this can explain some of the differences found on the efficacy of this treatment. Finally, all patients underwent at least one additional procedure, which creates a very heterogeneous study group.

Conclusions
This study demonstrated arthroscopic BMAC and CDM implantation appear to be safe and have the potential to improve patient outcomes in the short-term postoperative period.

References
1. Hjelle K, Solheim E, Strand T, Muri R, Britberg M. Articular cartilage defects in 1,000 knee arthroscopies. *Arthroscopy* 2002;18:730-734.
2. Widuchowski W, Widuchowski J, Trzaska T. Articular cartilage defects: Study of 25,124 knee arthroscopies. *Knee* 2007;14:177-182.
3. D’Ambrosi R, Valli F, De Luca P, Ursino N, Usuelli F. MaioRegen osteochondral substitute for the treatment of knee defects: A systematic review of the literature. *J Clin Med* 2019;8:783.
4. Buckwalter JA. Articular cartilage: injuries and potential for healing. *J Orthop Sports Phys Ther* 1998;28:192-202.
5. Scillia AJ, Aune KT, Andrachuk JS, et al. Return to play after chondroplasty of the knee in national football league athletes. *Am J Sports Med* 2015;43:663-668.
6. Ackermann J, Mestriner AB, Shah N, Gomoll AH. Effect of autogenous bone marrow aspirate treatment on magnetic resonance imaging integration of osteochondral allografts in the knee: A matched comparative imaging analysis. *Arthroscopy* 2019;35:2436-2444.
7. Perera JR, Gikas PD, Bentley G. The present state of treatments for articular cartilage defects in the knee. *Ann R Coll Surg Engl* 2012;94:381-387.
8. Rath B, Eschweiler J, Betsch M, Gruber G. Cartilage repair of the knee joint. *Orthopade* 2017;46:919-927 [in German].
9. Everhart JS, Campbell AB, Abouljoud MM, Kirven JC, Flanigan DC. Cost-efficacy of knee cartilage defect treatments in the United States. *Am J Sports Med* 2020;48:242-251.
10. Stevens HY, Shockley BE, Willett NJ, et al. Particulated juvenile articular cartilage implantation in the knee: A 3-year EPIC-μCT and histological examination. *Cartilage* 2014;5:74-77.
11. Widuchowski W, Lukasik P, Kwiatkowski G, et al. Isolated full thickness chondral injuries. Prevalence and outcome of treatment. A retrospective study of 5233 knee arthroscopies. *Acta Chir Orthop Traumatol Cech* 2008;75:382-386.
12. Rizzello G, Longo UG, Petrillo S, et al. Growth factors and stem cells for the management of anterior cruciate ligament tears. *Open Orthop J* 2012;6:525-530.
13. Fortier LA, Potter HG, Rickey EJ, et al. Concentrated bone marrow aspirate improves full-thickness cartilage repair compared with microfracture in the equine model. *J Bone Joint Surg Am* 2010;92:1927-1937.
14. Ivkovic A, Pascher A, Hudetz D, et al. Articular cartilage repair by genetically modified bone marrow aspirate in sheep. *Gene Ther* 2010;17:779-789.
15. Kon E, Rolli A, Filardo G, Tesi G, Marcacci M. Scaffold-based cartilage treatments: With or without cells? A systematic review of preclinical and clinical evidence. *Arthroscopy* 2015;31:767-775.
16. Mannfredini M, Zerbiniati F, Gildone A, Faccini R. Autologous chondrocyte implantation: a comparison between an open periosteal-covered and an arthroscopic matrix-guided technique. *Acta Orthop Belg* 2007;73:207-218.
17. Ferruzzi A, Buda R, Faldini C, et al. Autologous chondrocyte implantation in the knee joint: Open compared with arthroscopic technique. Comparison at a minimum follow-up of five years. *J Bone Joint Surg A* 2008;90:101.
18. Zielang F, Oberle D, Nierhoff C, Richter W, Moradi B, Schmitt H. Autologous chondrocyte implantation using the original periosteum-cover technique versus matrix-associated autologous chondrocyte implantation: A randomized clinical trial. *Am J Sports Med* 2010;38:924-933.
19. Chadha N, Dang A, Sampson E, et al. Porous cartilage-derived matrix scaffolds for repair of articular cartilage defects, Poster 0735. Proc ORS 2012, San Francisco, California.
20. Case JM, Scopp JM. Treatment of articular cartilage defects of the knee with microfracture and enhanced microfracture techniques. *Sports Med Arthrosc* 2016;24:63-68.
21. Goyal D, Keyhani S, Lee EH, Hui JHP. Evidence-based status of microfracture technique: A systematic review of Level I and II studies. *Arthroscopy* 2013;29:1579-1588.
22. Andrade R, Vasta S, Pereira R, et al. Knee donor-site morbidity after mosaicplasty—a systematic review. *J Exp Orthop* 2016;3.
23. Derrett S, Stokes EA, James M, Bartlett W, Bentley G. Cost and health status analysis after autologous chondrocyte implantation and mosaicplasty: A retrospective comparison. *Int J Technol Assess Health Care* 2005;21:359-367.
24. de Windt TS, Sorøe JC, Vonk LA, Kip MMA, Ijzerman MJ, Saris DBF. Early health economic modelling of
single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. *J Tissue Eng Regen Med* 2017;11:2950-2959.

25. Dávila Castrodad IM, Mease SJ, Werheim E, McNerney VK, Scillia AJ. Arthroscopic chondral defect repair with extracellular matrix scaffold and bone marrow aspirate concentrate. *Arthrosc Tech* 2020;9:e1241-e1247.

26. Dwyer T, Martin CR, Kendra R, et al. Reliability and validity of the arthroscopic international cartilage repair society classification system: Correlation with histological assessment of depth. *Arthroscopy* 2017;33:1219-1224.

27. Harris JD, Brand JC, Cote MP, Faucett SC, Dhawan A. Research pearls: The significance of statistics and perils of pooling. Part 1: Clinical versus statistical significance. *Arthroscopy* 2017;33:1102-1112.

28. Wang D, Chang B, Coxe FR, et al. Clinically meaningful improvement after treatment of cartilage defects of the knee with osteochondral grafts. *Am J Sports Med* 2019;47:71-81.

29. Jones KJ, Kelley BV, Arshi A, McAllister DR, Fabricant PD. Comparative effectiveness of cartilage repair with respect to the minimal clinically important difference. *Am J Sports Med* 2019;47:3284-3293.

30. Gobbi A, Whyte GP. One-stage cartilage repair using a hyaluronic acid-based scaffold with activated bone marrow-derived mesenchymal stem cells compared with microfracture. *Am J Sports Med* 2016;44:2846-2854.

31. Gobbi A, Chaurasia S, Karnatzikos G, Nakamura N. Matrix-induced autologous chondrocyte implantation versus multipotent stem cells for the treatment of large patellofemoral chondral lesions: A nonrandomized prospective trial. *Cartilage* 2015;6:82-97.

32. Carter AH, Guttierez N, Subhawong TK, et al. MR imaging of BioCartilage augmented microfracture surgery utilizing 2D MOCART and KOOS scores. *J Clin Orthop Trauma* 2018;9:146-152.

33. Pipino G, Risitano S, Alviano F, et al. Microfractures and hydrogel scaffolds in the treatment of osteochondral knee defects: A clinical and histological evaluation. *J Clin Orthop Trauma* 2019;10:67-75.

34. Piuzzi NS, Hussain ZB, Chahla J, et al. Variability in the preparation, reporting, and use of bone marrow aspirate concentrate in musculoskeletal disorders: A systematic review of the clinical orthopaedic literature. *J Bone Joint Surg Am* 2018;100:517-525.